Rekah Pharmaceutical Industry Ltd. (TLV:REKA)
Israel · Delayed Price · Currency is ILS · Price in ILA 1,065.00
+6.00 (0.57%)
Jun 19, 2026, 1:44 PM IDT
TLV:REKA Income Statement
Financials in millions ILS. Fiscal year is January - December.
Millions ILS. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 304.15 | 300.99 | 321.71 | 321.66 | 292.39 | 263.95 | |
Revenue Growth (YoY) | -1.31% | -6.44% | 0.01% | 10.01% | 10.78% | -0.57% |
Cost of Revenue | 236.86 | 231.42 | 249.76 | 241.46 | 213.69 | 198.79 |
Gross Profit | 67.29 | 69.57 | 71.95 | 80.2 | 78.71 | 65.16 |
Selling, General & Admin | 70.31 | 71.54 | 73.96 | 71.17 | 60.45 | 49.62 |
Research & Development | 4.31 | 4.3 | 3.83 | 3.65 | 3.23 | 2.08 |
Other Operating Expenses | 0.85 | 0.98 | 1.51 | 2.48 | 1.77 | 0.55 |
Operating Expenses | 75.48 | 76.81 | 79.29 | 77.3 | 65.46 | 52.25 |
Operating Income | -8.19 | -7.25 | -7.34 | 2.91 | 13.25 | 12.91 |
Interest Expense | -6.22 | -6.41 | -6.71 | -8.29 | -5.65 | -5.63 |
Interest & Investment Income | - | 0.37 | 0.36 | 0.71 | 0.04 | 0.07 |
Earnings From Equity Investments | 0.05 | -0.1 | 0.01 | -0.22 | - | -0.13 |
Currency Exchange Gain (Loss) | -0.25 | -0.25 | 0.04 | -0.32 | 0.14 | -0.79 |
Other Non Operating Income (Expenses) | -0.77 | -0.77 | -0.77 | -1.29 | -0.83 | 0.06 |
EBT Excluding Unusual Items | -15.38 | -14.41 | -14.4 | -6.5 | 6.96 | 6.48 |
Gain (Loss) on Sale of Investments | -0.01 | -0.01 | -0.02 | 0.02 | -0.02 | 1.19 |
Gain (Loss) on Sale of Assets | 0.16 | 0.16 | 23.71 | 0.05 | 0 | 0.05 |
Other Unusual Items | 2.98 | 3.06 | -1.36 | -0.62 | -6.59 | - |
Pretax Income | -12.24 | -11.2 | 7.93 | -7.05 | 0.36 | 7.71 |
Income Tax Expense | 6.3 | 6.88 | 1.72 | -0.14 | 2.4 | 1.1 |
Earnings From Continuing Operations | -18.54 | -18.07 | 6.21 | -6.91 | -2.04 | 6.61 |
Net Income to Company | -18.54 | -18.07 | 6.21 | -6.91 | -2.04 | 6.61 |
Minority Interest in Earnings | - | - | - | - | 0 | 0.01 |
Net Income | -18.54 | -18.07 | 6.21 | -6.91 | -2.04 | 6.62 |
Net Income to Common | -18.54 | -18.07 | 6.21 | -6.91 | -2.04 | 6.62 |
Net Income Growth | - | - | - | - | - | -38.65% |
Shares Outstanding (Basic) | 11 | 11 | 11 | 11 | 11 | 11 |
Shares Outstanding (Diluted) | 11 | 11 | 11 | 11 | 11 | 11 |
Shares Change (YoY) | -1.18% | - | - | - | - | - |
EPS (Basic) | -1.62 | -1.58 | 0.54 | -0.61 | -0.18 | 0.58 |
EPS (Diluted) | -1.62 | -1.58 | 0.54 | -0.61 | -0.18 | 0.58 |
EPS Growth | - | - | - | - | - | -38.65% |
Free Cash Flow | 3.36 | 5.92 | 17.85 | 16.86 | 32.07 | 7.68 |
Free Cash Flow Per Share | 0.29 | 0.52 | 1.56 | 1.48 | 2.81 | 0.67 |
Dividend Per Share | - | - | - | - | - | 0.868 |
Gross Margin | 22.12% | 23.11% | 22.36% | 24.93% | 26.92% | 24.69% |
Operating Margin | -2.69% | -2.41% | -2.28% | 0.90% | 4.53% | 4.89% |
Profit Margin | -6.09% | -6.00% | 1.93% | -2.15% | -0.70% | 2.51% |
Free Cash Flow Margin | 1.10% | 1.97% | 5.55% | 5.24% | 10.97% | 2.91% |
EBITDA | 13.84 | 15.34 | 25.18 | 32.82 | 40.73 | 35.77 |
EBITDA Margin | 4.55% | 5.10% | 7.83% | 10.20% | 13.93% | 13.55% |
D&A For EBITDA | 22.03 | 22.59 | 32.52 | 29.92 | 27.48 | 22.86 |
EBIT | -8.19 | -7.25 | -7.34 | 2.91 | 13.25 | 12.91 |
EBIT Margin | -2.69% | -2.41% | -2.28% | 0.90% | 4.53% | 4.89% |
Effective Tax Rate | - | - | 21.72% | - | 672.27% | 14.21% |
Advertising Expenses | - | 3.46 | 2.51 | 3.16 | 1.3 | 1.63 |